RxDoctor Payments Data

Karen Kahn, MD

Family Medicine · Ashland, ORNPI 1508865015

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $85,935 of the $86,183 with a category attached, or 99.7%. CSL Behring accounts for 75.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $18,614 and has fallen 77.0% since, to $4,285 in 2024. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,183in general payments, 2019–2025

Across 139 payments — averaging $620.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$65K
  • CSL Plasma Inc.$21K
  • Otsuka America Pharmaceutical, Inc.$123
  • Sunovion Pharmaceuticals Inc.$93
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$19
  • Avanir Pharmaceuticals, Inc.$13

What the payments were for

  • Consulting fees$85,935100%
  • Food & beverage$2480%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,183 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$7,577
Medicare patients
68
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban407$115,967
Invega SustennaPaliperidone Palmitate18$45,924
NuedextaDextromethorphan Hbr/Quinidine26$20,476
JardianceEmpagliflozin70$20,280
JanuviaSitagliptin Phosphate68$17,155
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$15,246
Bydureon BciseExenatide Microspheres12$10,656
Combivent RespimatIpratropium/Albuterol Sulfate18$9,434
XareltoRivaroxaban33$8,512
Paliperidone ErPaliperidone23$6,985
Gabapentin331$5,961
TradjentaLinagliptin20$5,448
Atorvastatin Calcium321$5,276
PremarinEstrogens, Conjugated11$5,195
BreynaBudesonide/Formoterol Fumarate34$5,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$13$20,47626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Ashland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →